Success Story: A Categorical Resident's Research on Heart Disease Earns NIW Approval
Client’s Testimonial:
"Thank you for your hard work through the process.”
On June 10th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Categorical Resident in the Field of Clinical Medicine (Approval Notice).
General Field: Clinical Medicine
Position at the Time of Case Filing: Categorical Resident
Country of Origin: United Kingdom
State of Residence at the Time of Filing: New York
Approval Notice Date: June 10th, 2026
Processing Time: 20 months, 8 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (Chen Immigration Law Associates) assisted a categorical resident from the United Kingdom whose work focuses on clinical medicine and cardiovascular outcomes research. His proposed endeavor centered on clinical epidemiological research and large-scale data synthesis involving complex cardiovascular pathologies, vascular disorders, and related critical cardiac conditions. The petition framed this work as nationally important because cardiovascular diseases remain a leading cause of mortality and unsustainable healthcare expenditures in the United States.
The client’s profile reflected both outstanding productivity and field reliance. At the time of filing, his evidentiary record included:
- At least 59 peer-reviewed journal articles
- 18 abstracts
- 2 preprints
- 3 book chapters
- At least 50 completed peer reviews
Our firm emphasized that these publications were not simply numerous; they had generated 1,360 citations, including 7 papers ranked in the top 0.01%, 3 in the top 0.1%, and 6 in the top 1% of most-cited clinical medicine articles for their publication years. These rankings helped show that independent researchers had turned to his work at a rate far exceeding ordinary citation patterns in the field.
The petition also connected the client’s research to practical clinical concerns. His studies helped clarify the global burden of cardiovascular disease, the disruption of cardiac testing during COVID-19, stroke awareness among at-risk populations, peripheral arterial disease trends, and inequities in cardiovascular research representation. Later researchers relied on his findings when discussing stroke prevention, pandemic-related cardiovascular care disruptions, and health disparities in clinical research.
This approval highlights the value of clinical medicine research that helps physicians and policymakers better interpret cardiovascular risk, improve disease management, and support evidence-based care for patients in the United States.